Protection with Recombinant Clostridium botulinum C1 And D Binding Domain Subunit (Hc) Vaccines Against C and D Neurotoxins

Authors

• Robert P. Webb, Integrated Toxicology Division, United States Army Medical Research Institute for Infectious Diseases, 1425 Porter Street, Frederick, MD
• Theresa J. Smith, Integrated Toxicology Division, United States Army Medical Research Institute for Infectious Diseases, 1425 Porter Street, Frederick, MD
• Patrick M. Wright, Integrated Toxicology Division, United States Army Medical Research Institute for Infectious Diseases, 1425 Porter Street, Frederick, MD
• Vicki A. Montgomery, Integrated Toxicology Division, United States Army Medical Research Institute for Infectious Diseases, 1425 Porter Street, Frederick, MD
• Michael M. Meagher, Department of Chemical Engineering, University of Nebraska-LincolnFollow
• Leonard A. Smith, Integrated Toxicology Division, United States Army Medical Research Institute for Infectious Diseases, 1425 Porter Street, Frederick, MDFollow

Document Type

Article

Date of this Version

2007

Comments

Published in Vaccine 25 (2007) 4273–4282.

Abstract

Recombinant botulinum Hc (rBoNT Hc) vaccines for serotypes C1 and D were produced in the yeast Pichia pastoris and used to determine protection against four distinct BoNT C and D toxin subtypes. Mice were vaccinated with rBoNT/C1 Hc, rBoNT/D Hc, or with a combination of both vaccines and challenged with BoNT C1, D, C/D, or D/C toxin. Mice receiving monovalent vaccinations were partially or completely protected against homologous toxin and not protected against heterologous toxin. Bivalent vaccine candidates completely survived challenges from all toxins except D/C toxin. These results indicate the recombinant C1 and D Hc vaccines are not only effective in a monovalent formula but offer complete protection against both parental and C/D mosaic toxin and partial protection against D/C mosaic toxin when delivered as a bivalent vaccine.